Sugammadex + Rocuronium
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Laryngoscopic Surgical Procedures
Conditions
Laryngoscopic Surgical Procedures
Trial Timeline
Jun 1, 2016 → Mar 1, 2018
NCT ID
NCT02451202About Sugammadex + Rocuronium
Sugammadex + Rocuronium is a approved stage product being developed by Merck for Laryngoscopic Surgical Procedures. The current trial status is completed. This product is registered under clinical trial identifier NCT02451202. Target conditions include Laryngoscopic Surgical Procedures.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02484651 | Approved | Completed |
| NCT02451202 | Approved | Completed |
| NCT00656799 | Phase 3 | Completed |
| NCT00475215 | Phase 3 | Completed |
| NCT00298831 | Phase 3 | Completed |